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The COVID-19 pandemic has reached most of the countries worldwide causing death, which often 25 
results from an inflammatory storm associated with severe acute respiratory syndrome (SARS). This 26 
has prompted researchers to seek specific novel and definitive treatments urgently. In this context, it is 27 
interesting to evaluate the preventive and therapeutic effects of existing pharmacological agents that 28 
could be useful. In this regard, vitamin D supplementation, particularly in individuals likely to be 29 
deficient, may be a promising option. Vitamin D is a hormone that modulates many of the same 30 
inflammatory and oxidative signaling pathways triggered during COVID-19. For example, vitamin D 31 
suppresses the actions of the renin-angiotensin system, which has a determining role in the 32 
pathophysiology of the inflammatory response related to COVID-19. This paper analyzes the evidence 33 
that vitamin D supplementation might be a valuable preventive/therapeutic measure in groups at risk of 34 
or infected with COVID-19. It also discusses how clinical studies could be best designed to evaluate 35 










Keywords  46 
COVID-19; vitamin D; inflammation; oxidative stress; renin-angiotensin system; prevention/treatment 47 




At present, multiple therapeutic strategies are being frantically sought to address the COVID-19 crisis. 49 
Among the most prominent approaches are the development of vaccines, anti-retroviral drugs, 50 
corticosteroids, and immunomodulatory drugs. Due to the urgency of the epidemic outbreak and the 51 
lack of sufficient experience with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 52 
some empirical treatments for COVID-19 are also proposed on a rational basis. More specifically, 53 
randomized controlled trials (RCTs) are lacking that support the benefit of vitamin D supplementation 54 
in the population and/or patients exposed to SARS-CoV-2. However, an ever-growing number of 55 
findings are strengthening and validating such claim.  56 
The system that integrates vitamin D has an ancestral origin that involves it with a primordial defense 57 
system. Vitamin D receptors (VDRs) were present in very primitive organisms that lacked skin, bones, 58 
cardiovascular systems, kidneys, and even lungs (20) indicating that the purpose must have been other 59 
than that conventionally known for vitamin D. More recently, VDRs were described in the cytoplasm, 60 
nuclear membrane, and even organelles such as mitochondria (21, 58). The genomic and non-genomic 61 
effects of vitamin D are ultimately the result of hormone-receptor binding that, after translocating to 62 
the nucleus, modulates the expression of genes involved in phospho-calcium metabolism (36, 45). At 63 
the same time, a considerable number of "non-classical" vitamin D actions have been described, 64 
including the inhibition of cell proliferation, secretion of other hormones, suppression of T-cell 65 
proliferation, and modulation of cytokines (14). Thus, vitamin D and its metabolites have been shown 66 
to participate actively in the regulation of innate and adaptive immune responses.  Consequently, its 67 
deficiency is associated with a series of infections, as well as autoimmune and allergic conditions (67). 68 
These data reinforce the original notion that the VDR-metabolite system would fulfill a central role in 69 
cellular and tissue defense through immune mechanisms and/or regulation of inflammatory processes. 70 
Furthermore, vitamin D would regulate the expression of 0.5 to 5% of the total human genome, which 71 
amounts to approximately 100 to 1,250 genes. Therefore, it is not surprising that vitamin D interacts 72 
with multiple genes commonly expressed in humans, such as those related to the renin-angiotensin-73 
aldosterone system (RAAS), among others (28). 74 
 75 
 76 
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Link between vitamin D/RAAS and COVID-19 77 
Apart from the immune system, evolution enabled vitamin D to interact with other fundamental 78 
systems in the maintenance of cellular homeostasis, such as the RAAS. As previously described in 79 
Figure 1 (20), Vitamin D opposes or modulates RAAS signaling pathways. RAAS regulates body 80 
hydroelectrolyte composition and hemodynamics. Of central interest for the present perspective, it also 81 
functions as a complex pro-inflammatory system (20). Consequently, most mammalian cells express 82 
both VDR and different RAAS receptors.  Vitamin D, its metabolites, and receptors, on the one hand, 83 
and RAAS molecules and its receptors, on the other, are part of a delicate cellular/tissue defense 84 
system mediating pro- and anti-inflammatory processes. 85 
Additionally, there are some close connections between COVID-19 and the RAAS, since serum 86 
angiotensin II (Ang II) levels in infected patients were significantly elevated and directly proportional 87 
to the viral load and lung damage observed (35). SARS-CoV-2 has been shown to bind to angiotensin-88 
converting enzyme 2 (ACE2) receptors to invade human lung epithelial cells and initiate the infection. 89 
At the same time, ACE2 produces anti-inflammatory, antioxidant, anti-fibrotic, and anti-hyperplasia 90 
effects. This leads to the degradation of Ang II at the lung level through the ACE2/Ang1-7/Mas 91 
receptor signaling pathway, i.e., the counter-regulatory RAAS axis with opposite actions to the 92 
classical RAAS axis (ACE/Ang II/AT1 receptor pathway). The increase in the degradation of Ang II 93 
prevents its toxic over-accumulation, which would cause the acute respiratory distress syndrome often 94 
present in COVID-19 (13, 18, 59, 69). Independently of COVID-19, RAAS is also involved in the 95 
regulation of lung tissue proliferation, inflammation, and fibrosis in several pulmonary pathologies, 96 
such as acute lung injury, asthma, pulmonary arterial hypertension, chronic obstructive pulmonary 97 
disease, and idiopathic pulmonary fibrosis, among others (62).  98 
Concerning vitamin D/RAAS interaction, the participation of the ACE2/Ang(1-7)/MasR signaling 99 
pathway has been recently demonstrated in hypertensive rats (17). In humans, vitamin D was found to 100 
act as a cofactor in the attenuation of incident atrial fibrillation by RAAS inhibition (68). Additionally, 101 
exacerbated RAAS activation at the hepatic level causes liver dysfunction and increases the risk of 102 
developing diabetes mellitus. In this regard, calcitriol was shown to modulate the altered upregulation 103 
of liver RAAS under conditions of insulin resistance in mice (33). Vitamin D is a potent suppressor of 104 
renin production (Figure 1) (20). Thus, low plasma levels of vitamin D are associated with an increase 105 
in renin synthesis, which results in over-activation of RAAS and increased production of Ang II, and 106 
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vice versa (34, 55). It has been demonstrated that vitamin D deficiency also results in overexpression 107 
of angiotensin-converting enzymes (ACE and ACE2) (73). Furthermore, in patients with D 108 
hypovitaminosis, the re-establishment of normal vitamin D levels causes blockade of peripheral RAAS 109 
(9). 110 
In vitamin D receptor-null mice, the development of induced acute lung injury was found to be more 111 
severe than in wild-type mice, together with increased levels of pulmonary Ang II and renin. 112 
Pretreatment of vitamin D receptor-null mice with losartan reduced the severity of pulmonary injury 113 
indicating that vitamin D, via its receptors, attenuates acute lung injury by blocking RAAS (30). 114 
Additionally, Xu et al. showed that calcitriol inhibits ACE and induces ACE2 expression in rat lung 115 
while reducing Ang II levels and inhibiting AT1R expression. The authors suggest that VDR 116 
activation may exert protective effects on LPS-induced lung injury by regulating the balance between 117 
RAAS members (73). Moreover, if vitamin D deficiency is chronic, the uncontrolled RAAS over-118 
activation for extended periods may induce pulmonary fibrosis through the exacerbated and 119 
accelerated increase in extracellular matrix deposition in lung tissues (56).  120 
Lung epithelial cells exhibit a high expression of enzyme 1 α-hydroxylase allowing for the local 121 
synthesis of 1,25-dihydroxyvitamin D -the most active form of vitamin D- also called calcitriol. 122 
Calcitriol inhibits the production and secretion of many cytokines from bronchial smooth muscle cells, 123 
such as platelet-derived growth factor, RANTES (regulator in the activation of expressed and secreted 124 
normal T cells), and matrix metalloproteinases, leading to reduced proliferation and inflammation in 125 
lung smooth muscle cells. Vitamin D stimulates the synthesis of interleukin 10 by CD4+ CD25+ 126 
Foxp3+ and T-regulatory cells. At the same time, it inhibits the activation of dendritic cells by 127 
downregulating the expression of CD80/86 and CD40. Furthermore, vitamin D stimulates the 128 
expression of cathelicidin and many other anti-infective molecules (12, 15, 54).  129 
Supplementation with 1,25-dihydroxyvitamin D suppresses the recruitment of eosinophils and 130 
lymphocytes into the airways, decreases IL-4 production of T cells, and inhibits T cell migration by 131 
attenuating the inflammatory response (66). It also works as an adjuvant for other therapies, such as 132 
immunotherapy against allergens (60). Simultaneous administration of vitamin D and dexamethasone 133 
in steroid-resistant asthmatic patients increased IL-10 synthesis to levels similar to those found in 134 
steroid-sensitive patients treated with dexamethasone alone (74). 135 
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In a rat model of asthma, vitamin D treatment significantly reduced serum IgE and eotaxin levels (65). 136 
Additionally, it decreased the infiltration of inflammatory cells in the airways, serum levels of IL-6, 137 
tumor necrosis factor-alpha (TNFα), and IL-1β, as well as the expression of the apoptotic protein 138 
associated with Bcl 2, caspase-3, TLR4, nuclear factor kappa B (NF-κB), and phosphorylated p65 NF-139 
κB. As a result, vitamin D raised serum levels of IL-10 reducing the inflammatory and apoptotic 140 
response in this rat model of asthma (77). Importantly, vitamin D suppressed the synthesis of 8-141 
isoprostane (8-iso), IL-6, and granulocyte-macrophage colony-stimulating factors in human bronchial 142 
epithelial cells exposed to contaminating particles. Vitamin D also increased the expression of genes of 143 
the G6PD antioxidant pathway and the levels of oxidized glutathione. Therefore, vitamin D seems to 144 
protect the lungs and airways of asthma patients through its anti-inflammatory and antioxidant effects 145 
(46). (Figure 2) 146 
In the murine model of bleomycin-induced lung inflammation, calcitriol reduced early lung 147 
inflammation by attenuating immune cell infiltration, suppressing the secretion of inflammatory 148 
cytokines, blocking translocation of NF-κB p65, inhibiting phosphorylation of lung p38 MAPK and 149 
protein kinase B (Akt). It also attenuated the expression of smooth muscle alpha-actin (a marker for 150 
epithelial-mesenchymal transition in the lungs, which promotes fibrosis) while decreasing the 151 
phosphorylation of Smad and the up-regulation of transforming growth factor-beta 1 (TGF-β1) (63). In 152 
addition, calcitriol caused a 40% reduction in the recruitment of neutrophils to the lungs in an animal 153 
model of acute lung injury. The anti-inflammatory effect of vitamin D may be mediated by the 154 
inhibition of IL-8 secretion at the lung level (61).  155 
Administration of vitamin D to neonatal rats exhibiting hyperoxia-induced lung injury (as a model of 156 
bronchopulmonary dysplasia) attenuated lung injury through various protective actions, such as 157 
preserving the integrity of lung structure, decreasing inflammation by negatively regulating TLR4 158 
activation, and reducing extracellular matrix deposition and the inhibition of lung cell apoptosis (75). 159 
Vitamin D was also shown to have immunomodulatory and anti-inflammatory effects in the treatment 160 
of cystic fibrosis of the airways, as it reduces the expression of CD279 (PD-1) in CD4+ and CD8+ T 161 
cells. Furthermore, vitamin D decreases the frequency of CD8+ T and invariant mucosa-associated T 162 
cells that co-express activation markers for CD38 and D antigen in human leukocytes. Therefore, 163 
vitamin D treatment would prevent the progression of lung damage associated with cystic fibrosis of 164 
the airways (49). (Figure 2) 165 
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Vitamin D lung-protection: A rational approach to COVID-19  166 
Oxidative stress caused by tobacco smoke is known to worsen the progression of chronic obstructive 167 
pulmonary disease (COPD). In this sense, vitamin D has also been proposed as a natural anti-168 
inflammatory and antioxidant capable of improving the prognosis of this pulmonary pathology in 169 
smokers (6). COPD patients were shown to have lower plasma vitamin D levels than healthy patients, 170 
suggesting a possible correlation between weak antioxidant defense and the development of this lung 171 
disease (1). In this respect, a few years ago, our group raised the discussion about a worldwide 172 
pandemic of vitamin D deficiency as a possible explanation for the high cellular inflammatory activity 173 
induced by RAAS (20). The original discussion involved a significant number of pathologies, mainly 174 
cardiovascular, although all of them with a similar inflammatory basis. Currently, with the main focus 175 
on acute lung inflammation caused by COVID-19, the Irish Longitudinal Study on Aging (TILDA 176 
2020) reinforces the idea that adequate vitamin D supplementation, especially in older people, may be 177 
beneficial for the vulnerable population during the COVID-19 outbreak (31).  178 
In summary, the anti-inflammatory, antioxidant, and antiviral properties of vitamin D, in addition to its 179 
ability to modulate RAAS, make it an attractive strategy for preventing COVID-19 and its associated 180 
organic damage (5). (Figure 2) 181 
 182 
Promising results according to vitamin D levels and supplementation 183 
An increasing number of papers, including systematic reviews and meta-analyses, confirm the link 184 
between a higher incidence of severe COVID-19, including death, and low serum levels of vitamin D. 185 
Remarkably, serum vitamin D concentration was inversely associated with the risk and severity of 186 
acute respiratory tract infection (47). A fundamental analysis of the link between vitamin D deficiency 187 
and its treatment, associated with the incidence of COVID-19, was performed by Meltzer and 188 
colleagues using data from the electronic health record at the University of Chicago Medicine. The 189 
main result of this analysis is the comparison of patients with a low measured basal level of vitamin D   190 
and no supplementation treatment versus patients with a low basal level of vitamin D but 191 
supplemented with this vitamin. The non-supplemented group showed a significantly higher number of 192 
positive tests for COVID-19. Among the treated patients, the vitamin D protective effect against the 193 
SAR-CoV-2 virus infection was significant only in the group with basal vitamin D-deficiency (40).  194 
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Additionally, there is robust information showing that as vitamin D levels increase, the number and 195 
severity of respiratory infections decrease (70, 76). Several studies that evaluated the role of vitamin D 196 
in respiratory viral infections, using different methodologies and dosages and comparing vitamin D 197 
supplementation vs. placebo, have mostly found a positive effect for vitamin D (4, 26). Although the 198 
mechanisms are not fully understood, the combined improvements in the immunomodulatory and anti-199 
inflammatory response, together with the proven germicidal effects of vitamin D, take part in its 200 
protective effects. This background provides the medical community with enough support to 201 
investigate whether vitamin D effects are also beneficial in the context of COVID-19. 202 
Different strategies are available to increase vitamin D levels: Food fortification programs, increasing 203 
sun exposure by stimulating outdoor activities, and vitamin D supplementation, among others. Both 204 
vitamin D food fortification and sun exposure are useful to improve low serum levels of vitamin D. It 205 
is evident that this strategy enhances human defense against viral and bacterial infection. Vitamin D 206 
food fortification represents both a feasible and recommended measure, whose implementation as a 207 
health policy was suggested in a recent review, taking as a guide the program used in Finland. The 208 
related legislation, however, must be generated by each of the interested countries (48). Both historical 209 
and recent evidence on the mechanisms of sun-dependent vitamin D production and its protective 210 
effects were reviewed by Wacker and Holick (71). It is worth noting that the cutaneous production of 211 
vitamin D depends on many variables. The lower rates of skin vitamin D production occur among 212 
individuals with darker skin or reduced sun exposure, subjects living in higher latitudes in winter, 213 
nursing home residents, or elderly people. Accordingly, COVID-19 is more prevalent among African 214 
Americans, individuals living in northern cities in late winter, and older adults, all of whom have an 215 
increased risk of vitamin D deficiency (39). As shown in a recent systematic review and meta-analysis 216 
(42), vitamin D supplementation is superior to sunbathing at elevating vitamin D serum levels. 217 
However, increasing sun exposure or improving the general health condition of the population at high 218 
risk of vitamin D deficiency described above is not easy to achieve. This explains the key role of 219 
vitamin D supplementation. Notwithstanding this, a balanced and healthy diet that includes foods with 220 
high vitamin D content, along with an exercise routine, preferably outdoors, aimed at reducing or at 221 
least maintaining body weight and improving aerobic capacity are essential preventive strategies to 222 
enhance the defenses against SARS-CoV-2 (41).   223 
Recently, Grant and colleagues suggested that vitamin D supplementation could reduce the risk of 224 
influenza and COVID-19 infections (24). This conclusion is in line with the existence of abundant data 225 
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in support of the protective action of vitamin D in multiple inflammatory and oxidative pulmonary 226 
diseases, such as that caused by SARS-CoV-2. Grant et al. showed that the degree of protection 227 
against influenza and COVID-19 increases as vitamin D levels increase. However, the results have not 228 
allowed establishing an adequate cut point level yet. Nonetheless, an observational study reported that 229 
38 ng vitamin D/mL is an appropriate serum value to decrease the risk of acute viral respiratory 230 
infections (53). Additionally, some authors suggest maintaining a serum vitamin D level of at least 30 231 
ng/mL or even within a range of between 40-60 ng/mL to reduce infectious processes. Thus, it has 232 
been reported that post-surgical hospital infections are three times higher when vitamin D values are 233 
lower than 30 ng/mL (51), and that these types of infections were reduced by 33% for every 10 ng/mL 234 
of increase in serum vitamin D (32) levels. 235 
Following medical evidence, frequent clinical behavior suggests that in the face of severe vitamin D 236 
deficiency, a two-stage therapeutic scheme should be established. The first stage consists of a high 237 
loading dose followed by a lower maintenance dose. In this regard, the use of the so-called "loading 238 
dose" of vitamin D has been reported to achieve a target plasma level of 30 ng/mL vitamin D by using 239 
different dosage regimens (daily, weekly, biweekly, and monthly). Remarkably, in patients with 240 
elevated inflammatory markers -such as obese subjects- the necessary supplementation should be two 241 
to threefold higher than that established for the general population. In the case of overweight patients, 242 
such supplementation should be at least 1.5 times higher than the general population (19). 243 
Even though knowledge about the role of vitamin D is still scarce, pooled data support its role as an 244 
adjuvant strategy aimed at providing rapid and effective protection against the risk of infection by 245 
SARS-CoV-2. In this scenario, different approaches have been tried, such as daily vitamin D doses for 246 
a short time or the use of an initial loading dose followed by high vitamin D doses for a short time. In 247 
each case, and in times of pandemic, this allows achieving plasma concentrations within appropriate 248 
ranges of 30-50 ng/mL or higher. More specifically, strategies such as that suggested by Grant et al. 249 
propose a dose of 10,000 IU/day for a month to quickly reach the goal of 40-60 ng vitamin D/mL, 250 
followed by 5,000 IU/day for a few more weeks (23). 251 
The proposed level of high vitamin D doses is striking, neglecting its possible toxic effects; however, 252 
in this respect, some studies show that a dose of 10,000 IU/day for 4-6 months has no adverse effects. 253 
Amir et al. verified no toxic effects in Canadian women with breast cancer and bone metastases (2). 254 
Similarly, the research team led by Dr. Holick -one of the most prominent groups in vitamin D studies- 255 
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supplemented cancer patients with high doses of vitamin D finding no toxicity; on the contrary, it 256 
improved the intestinal microbiota of treated patients (11). The same group worked with 10,000 257 
IU/day for 6 months without causing hypercalcemia and achieving vitamin D levels of the order of 258 
78.6±13 ng/mL (57). Another study treated psychiatric patients with doses of 5,000 or 50,000 IU/day 259 
for 16 months without adverse effects. The only caveat was that if a patient also received calcium 260 
supplementation, the dose should not be high to minimize the risk of hypercalcemia (38). The bet was 261 
higher in other works with proposals for an initial dose of 100,000 IU to achieve serum concentrations 262 
above 20 ng/mL, an initial dose of 300,000 IU for levels above 30 ng/mL, and even an initial dose of 263 
500,000 IU for healthy adults (16, 29). In another clinical trial, a monthly dose of 100,000 IU 264 
increased neither the incidence rate of kidney stone events nor of hypercalcemia (37).  265 
Current information is controversial regarding what should be the supplemental dose of vitamin D to 266 
be administered to patients. Age, diet, weight, sun exposure, and concomitant diseases may have 267 
clinical relevance because they may change the requirements and production capacity. Consider the 268 
dose of vitamin D needed to attain its bone action; the maximum dose suggested for this purpose is 269 
4,000 IU daily. Nevertheless, the optimal serum level needed to protect our body against infections 270 
remains unclear. In this sense, serum levels of 50 to 60 ng vitamin D/mL seem to be adequate. With 271 
11,000 IU vitamin D/day, it takes about four weeks to achieve the above serum levels, and with 4,000 272 
IU vitamin D/day, it takes over 12 weeks. The proposed higher dose is not associated with an 273 
increased risk of toxicity. In a recently published Consensus, it was suggested that doses ranging from 274 
4,000 IU (for bone action) to 10,000 IU (for non-calcemic effects) are safe and effective to achieve the 275 
advantageous effects of vitamin D (22, 23, 27). However, additional studies are required to confirm 276 
what is the best protection threshold against COVID-19 or to treat recently infected patients (10). 277 
Based on scarce information comparing a high single dose versus daily doses of vitamin D, some 278 
authors have expressed concern about data that show better results with daily doses of vitamin D. 279 
However, it is interesting to note that the endpoint evaluated in this randomized study was not 280 
infectious diseases (3). Additionally, in a recent publication of a randomized trial, 120 children with a 281 
confirmed diagnosis of sepsis were assigned to receive either a single dose of 150,000 IU of vitamin 282 
D3 or a placebo. SOFA score and the percentage of children with septic shock were lower in the 283 
vitamin D group (72).  284 
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Finally, latest reports have proposed that vitamin D supplementation could improve the clinical course 285 
of patients infected with SARS-CoV-2 (8, 43). The same recommendation was reinforced by Grant 286 
and colleagues, who suggested that vitamin D supplementation, could reduce the risk of COVID-19 287 
(24). 288 
 289 
Conclusion and prospects 290 
To sum up, and in the face of this devastating epidemic for which we still lack effective treatments, the 291 
present perspective proposes to explore the potentially protective effect of high doses of vitamin D to 292 
increase blood and tissue levels rapidly. This approach intends to counteract RAAS overload, thus 293 
improving the course of COVID-19 and its respiratory complications, even protecting other organs. 294 
The purpose is to open the discussion and create an appropriate debate on the prospect of prescribing 295 
vitamin D to the general population -particularly the most vulnerable- as well as achieving a serum and 296 
tissue vitamin D level to counteract the imbalance of some RAAS and manifest its anti-inflammatory 297 
effects. 298 
We believe that this strategy applied at the population level could provide an additional tool for the 299 
defense against the SARS-CoV-2 virus without adverse effects, as demonstrated in the review of more 300 
than 76,000 patients included in controlled trials with vitamin D supplementation. A possible dose to 301 
obtain rapid increases in plasma vitamin D levels could range between 5,000 IU and/or 10,000 IU 302 
daily, or 50,000 IU to 100,000 IU weekly (7). Given the tentativeness of the proposed dose, the use of 303 
lower doses could be considered in children or young adults with low exposure risk to the virus. In this 304 
regard, our working group is advancing in the development of controlled protocols with different 305 
populations of people at risk or already infected, evaluating physiological parameters and clinical 306 
events. Even though said intervention does not intend to eliminate the virus, its potential is promising 307 
to hinder viral entry and/or improve patient evolution. That is, vitamin D intake could improve the 308 
health of the patients so that they can be in better shape to face COVID-19 and boost their defenses 309 
against this infection, or even against other equivalent diseases. Furthermore, it should be borne in 310 
mind that quarantine, as a protection strategy for the population against infection, complicates the 311 
defense mechanisms due to a significant decline in serum vitamin D levels by reduced sun exposure. 312 
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As previously described, we consider that the present recommendation finds support in multiple 313 
reports. Accordingly, Grant and colleagues recently proposed to raise serum vitamin D concentrations 314 
through supplementation claiming that this strategy could reduce the incidence, severity, and risk of 315 
death from influenza, pneumonia, and the current COVID- 19 epidemic (25). Additionally, Panarese 316 
and Shahini proposed the prophylactic use of usual vitamin D doses to mitigate the aggressive 317 
progression of the disease in Europe (44). In turn, Rhodes and collaborators have proposed vitamin D 318 
supplementation, at least for people in the northern hemisphere who are at higher risk of severe illness 319 
and death (52). The same is recommended by the United Kingdom Association of Dietitians (64). 320 
Finally, ten RCTs around the world (50), including one by our group (# NCT04411446), are currently 321 
investigating whether supplementation with vitamin D could be an effective strategy against viral 322 
complications. Such trials aim to validate this hypothesis for the benefit of public health, particularly 323 
in the context of the COVID-19 crisis. 324 
 325 
Funding 326 
This work was supported by grants from the Research and Technology Council of Cuyo University 327 
(SECyT), Mendoza, Argentina, and from ANPCyT FONCyT, both of which were awarded to Walter 328 
Manucha. Grant no. PICT 2016-4541, and IP-COVID-19-931. 329 
Declaration of conflicting interest 330 
The author(s) declare no potential conflicts of interest concerning the research, authorship, and/or 331 
publication of this article. 332 
Acknowledgments 333 
The authors are grateful to Elena M.V. de Cavanagh, Ph.D. - Instituto Massone SA, Arias 3751 - 334 
(C1430CRC), Buenos Aires, Argentina, (+54 9 11) 45656910, for critical reading of the manuscript. 335 
 336 
 337 




1. Al-Azzawi MA, Ghoneim AH, Elmadbouh I. Evaluation of Vitamin D, Vitamin D Binding 339 
Protein Gene Polymorphism with Oxidant - Antioxidant Profiles in Chronic Obstructive Pulmonary 340 
Disease.  J Med Biochem 36: 331-340, 2017. 341 
2. Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M. 342 
A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer 343 
patients with bone metastases. Cancer 116: 284-291, 2010. 344 
3. Apaydin M, Can AG, Kizilgul M,  Beysel S,  Kan S, Caliskan M, Demirci T, Ozcelik 345 
O,  Ozbek M, Cakal E. The effects of single high-dose or daily low-dosage oral cholecalciferol 346 
treatment on vitamin D levels and muscle strength in postmenopausal women. BMC Endocr 347 
Disord 18(1): 48, 2018. 348 
4. Arihiro S, Nakashima A, Matsuoka M, Suto S, Uchiyama K, Kato T, Mitobe J, Komoike N, 349 
Itagaki M, Miyakawa Y, Koido S, Hokari A, Saruta M, Tajiri H, Matsuura T, Urashima M. 350 
Randomized trial of vitamin D supplementation to prevent seasonal influenza and upper respiratory 351 
infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 25: 1088-1095, 2019. 352 
5. Aygun H. Vitamin D can prevent COVID-19 infection-induced multiple organ damage. Naunyn 353 
Schmiedebergs Arch Pharmacol 1-4, 2020. 354 
6. Biswas S, Hwang JW, Kirkham PA, Rahman I. Pharmacological and dietary antioxidant 355 
therapies for chronic obstructive pulmonary disease.  Curr Med Chem 20: 1496-530, 2013. 356 
7. Bolland M, Grey A, Gamble G, Reid I. The effect of vitamin D supplementation on skeletal, 357 
vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2: 307-20, 358 
2014. 359 
8. Carpagnano GE, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, Palumbo A, Di 360 
Gioia G, Valerio VN, Resta O. Vitamin D deficiency as a predictor of poor prognosis in patients with 361 
acute respiratory failure due to COVID-19. J Endocrinol Invest. 1-7, 2020. doi:10.1007/s40618-020-362 
01370-x 363 
Downloaded from journals.physiology.org/journal/ajplung (186.058.135.140) on October 30, 2020.
14 
 
9. Carrara D, Bruno RM, Bacca A, Taddei S, Duranti E, Ghiadoni L, Bernini G. Cholecalciferol 364 
treatment downregulates renin-angiotensin system and improves endothelial function in essential 365 
hypertensive patients with hypovitaminosis D. J Hypertens 34: 2199–2205, 2016. 366 
10. Chakhtoura M, Napoli N, El Hajj Fuleihan G. Commentary: Myths and facts on vitamin D 367 
amidst the COVID-19 pandemic. Metabolism 109: 154276, 2020. doi:10.1016/j.metabol.2020.154276. 368 
11. Charoenngam N, Shirvani A, Kalajian TA, Song A, Holick MF. The Effect of Various Doses of 369 
Oral Vitamin D3 Supplementation on Gut Microbiota in Healthy Adults: A Randomized, Double-370 
blinded, Dose-response Study. Anticancer Res 40: 551-556, 2020. 371 
12. Chen WW, Cai XX, Tian WM, Shang YX. Expression of RANTES in the lung tissue of 372 
asthmatic rats, and the intervention effect of vitamin D on RANTES expression. Zhongguo Dang Dai 373 
Er Ke Za Zhi 14: 863-868, 2012. 374 
13. Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and 375 
its effect on the prognosis of COVID-19. J Med Virol 92(7): 726-730, 2020. 376 
14. Christakos S, Raval-Pandya M, Wernyj RP, Yang W. Genomic mechanisms involved in the 377 
pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J 316 ( Pt 2): 361-71, 1996. 378 
15. Chung C, Silwal P, Kim I, Modlin RL, Jo EK. Vitamin D-Cathelicidin Axis: at the Crossroads 379 
between Protective Immunity and Pathological Inflammation during Infection. Immune Netw 20(2): 380 
e12, 2020. doi:10.4110/in.2020.20.e12. 381 
16. Cipriani A, Romagnoli E, Scillitani A, Chiodini I, Clerico R, Carnevale V, Mascia ML, 382 
Battista C, Viti R, Pileri M, Eller-Vainicher C, Minisola S. Effect of a Single Oral Dose of 600,000 383 
IU of Cholecalciferol on Serum Calciotropic Hormones in Young Subjects With Vitamin D 384 
Deficiency: A Prospective Intervention Study. J Clin Endocrinol Metab 95: 4771-4777, 2010.  385 
17. Cui C, Xu P, Li G, Qiao Y, Han W, Geng C, Liao D, Yang M, Chen D, Jiang P. Vitamin D 386 
receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive 387 
rats and angiotensin II-exposed microglial cells: Role of renin-angiotensin system. Redox Biol 26: 388 
101295, 2019. https://doi.org/10.1016/j.redox.2019.101295. 389 
Downloaded from journals.physiology.org/journal/ajplung (186.058.135.140) on October 30, 2020.
15 
 
18. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 390 
Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System 391 
Blockers. Hypertension 75(6): 1382-1385, 2020. 392 
19. Ekwaru JP, Zwicker JD, Holick MF, Giovannucci E, Veugelers PJ. The importance of body 393 
weight for the dose response relationship of oral vitamin D supplementation and serum 25-394 
hydroxyvitamin D in healthy volunteers. PLoS One 9: e111265, 2014. 395 
doi:10.1371/journal.pone.0111265. 396 
20. Ferder M, Inserra F, Manucha W, Ferder L. The world pandemic of vitamin D deficiency 397 
could possibly be explained by cellular inflammatory response activity induced by the renin-398 
angiotensin system. Am J Physiol Cell Physiol 304(11): C1027-39, 2013. doi: 399 
10.1152/ajpcell.00403.2011. 400 
21. García IM, Altamirano L, Mazzei L, Fornés M, Molina MN, Ferder L, Manucha W. Role of 401 
mitochondria in paricalcitol-mediated cytoprotection during obstructive nephropathy. Am J Physiol 402 
Renal Physiol 302(12): F1595-605, 2012. doi: 10.1152/ajprenal.00617.2011. 403 
22. Giustina A, Adler RA,  Binkley N, Bollerslev J Bouillon R Dawson-Hughes B, Ebeling PR, 404 
Feldman D, Formenti AM, Lazaretti-Castro M, Marcocci C, Rizzoli R, Sempos CT, Bilezikian 405 
JP. Consensus statement from 2nd International Conference on Controversies in Vitamin D. Rev 406 
Endocr Metab Disord 21: 89–116, 2020. 407 
23. Grant WB, Baggerly CA, Lahore H. Reply: “Vitamin D Supplementation in Influenza and 408 
COVID-19 Infections. Comment on: Evidence That Vitamin D Supplementation Could Reduce Risk 409 
of Influenza and COVID-19 Infections and Deaths Nutrients 2020, 12(4), 988”. Nutrients 12: 1620, 410 
2020. doi:10.3390/nu12061620.  411 
24. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. 412 
Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections 413 
and Deaths. Nutrients 12(4): pii: E988, 2020. doi: 10.3390/nu12040988. 414 
25. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. 415 
Vitamin D Supplementation Could Prevent and Treat Influenza, Coronavirus, and Pneumonia 416 
Infections. Preprints 2020030235, 2020. doi: 10.20944/preprints202003.0235.v1. 417 
Downloaded from journals.physiology.org/journal/ajplung (186.058.135.140) on October 30, 2020.
16 
 
26. Gruber-Bzura BM. Vitamin D and influenza - Prevention or therapy? Int J Mol Sci 19: 2419, 418 
2018. 419 
27. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux M. Human serum 25-420 
hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 77: 204–421 
210, 2003. 422 
28. Hossein-nezhad A, Spira A, Holick MF. Influence of vitamin D status and vitamin D3 423 
supplementation on genome wide expression of white blood cells: a randomized double-blind clinical 424 
trial. PLoS One 8(3): e58725, 2013. doi:10.1371/journal.pone.0058725 425 
29. Kearns MD, Alvarez JA, Tangpricha V. Large, single-dose, oral vitamin D supplementation in 426 
adult populations: a systematic review. Endocr Pract 20: 341-351, 2014. 427 
30. Kong J, Zhu X, Shi Y, Liu T, Chen Y, Bhan I, Zhao Q, Thadhani R, Li YC. VDR attenuates 428 
acute lung injury by blocking Ang-2-Tie-2 pathway and renin-angiotensin system. Mol Endocrinol 27: 429 
2116-2125, 2013.  430 
31. Laird E, Kenny RA. The Irish Longitudinal Study of Ageing (TILDA). 2020. 431 
doi.org/10.38018/TildaRe.2020-05. 432 
32. Laviano E, Sanchez Rubio M, González-Nicolás MT, Palacian MP, López J, Gilaberte Y, 433 
Calmarza P, Rezusta A, Serrablo A. Association between preoperative levels of 25-hydroxyvitamin 434 
D and hospital-acquired infections after hepatobiliary surgery: A prospective study in a third-level 435 
hospital. PLoS One 15(3): e0230336, 2020. doi: 10.1371/journal.pone.0230336. 436 
33. Leung PS. The Modulatory Action of Vitamin D on the Renin-Angiotensin System and the 437 
Determination of Hepatic Insulin Resistance. Molecules 24: pii: E2479, 2019. 438 
https://doi.org/10.3390/molecules24132479. 439 
34. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine 440 
regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 89-90: 387-441 
392, 2004.   442 
Downloaded from journals.physiology.org/journal/ajplung (186.058.135.140) on October 30, 2020.
17 
 
35. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, Zhang Z, 443 
Wang L, Peng L, Chen L, Qin Y, Zhao D, Tan S, Yin L, Xu J, Zhou C, Jiang C, Liu L. Clinical 444 
and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci 445 
China Life Sci 63: 364-374, 2020. 446 
36. Máčová L, Bičíková M, Hampl R. Impaired vitamin D sensitivity. Physiol Res 67(3): S391-S400, 447 
2018. 448 
37. Malihi Z, Lawes CMM, Wu Z, Huang Y, Waayer D, Toop L, Khaw KT, Camargo CA, 449 
Scragg R.  Monthly high-dose vitamin D supplementation does not increase kidney stone risk or 450 
serum calcium: results from a randomized controlled trial. Am J Clin Nutr 109(6): 1578-1587, 2019. 451 
38. McCullough PJ, Lehrer DS, Amend J. Daily oral dosing of vitamin D3 using 5,000 to 50,000 452 
international units a day in long-term hospitalized patients: Insights from a seven year experience. J 453 
Steroid Biochem Mol Biol 189: 228-239, 2019. 454 
39. Meftahi GH, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of 455 
cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-456 
aging". Inflamm Res 1-15, 2020. 457 
40. Meltzer DO,  Best TJ, Zhang H, Vokes T, Arora V,  Solway J. Association of Vitamin D 458 
Deficiency and Treatment with COVID-19 Incidence. medRxiv 2020.05.08.20095893, 2020. doi: 459 
10.1101/2020.05.08.20095893. 460 
41. Mohamed AA, Alawna M. Role of increasing the aerobic capacity on improving the function of 461 
immune and respiratory systems in patients with coronavirus (COVID-19): A review. Diabetes Metab 462 
Syndr 14(4): 489-496, 2020. 463 
42. Moradi S, Shahdadian F, Mohammadi H, Rouhani MH. A comparison of the effect of 464 
supplementation and sunlight exposure on serum vitamin D and parathyroid hormone: A systematic 465 
review and meta-analysis. Crit Rev Food Sci Nutr 60(11): 1881‐1889, 2020.  466 
43. Panagiotou G, Tee SA, Ihsan Y, Athar W, Marchitelli G, Kelly D, Boot CS, Stock N, 467 
Macfarlane J, Martineau AR, Burns G, Quinton R. Low serum 25-hydroxyvitamin D (25[OH]D) 468 
Downloaded from journals.physiology.org/journal/ajplung (186.058.135.140) on October 30, 2020.
18 
 
levels in patients hospitalised with COVID-19 are associated with greater disease severity. Clin 469 
Endocrinol (Oxf). 2020;10.1111/cen.14276. doi:10.1111/cen.14276 470 
44. Panarese  A, Shahini E. Letter: Covid-19, and Vitamin D. Aliment Pharmacol Ther 51(10): 993-471 
995, 2020.  472 
45. Perret C, Colnot S, Romagnolo B, Thomasset M. Control of nuclear transcription of vitamin D-473 
dependent genes by vitamin D. Curr Opin Nephrol Hypertens 6(4): 314-20, 1997. 474 
46. Pfeffer PE, Lu H, Mann EH, Chen YH, Ho TR, Cousins DJ, Corrigan C, Kelly FJ, Mudway 475 
IS, Hawrylowicz CM. Effects of vitamin D on inflammatory and oxidative stress responses of human 476 
bronchial epithelial cells exposed to particulate matter.  PLoS One 13: e0200040, 2018. 477 
doi.org/10.1371/journal.pone.0200040. 478 
47. Pham H, Rahman A, Majidi A, Waterhouse M, Neale RE. Acute Respiratory Tract Infection 479 
and 25-Hydroxyvitamin D Concentration: A Systematic Review and Meta-Analysis. Int J Environ Res 480 
Public Health 16: 3020, 2019. doi:10.3390/ijerph16173020. 481 
48. Pilz S, März W, Cashman KD, Kiely M,  Whiting SJ, Holick MF, Grant WB, Pludowski P, 482 
Hiligsmann M, Trummer C, Schwetz V, Lerchbaum E, Pandis M, Tomaschitz A, Grübler MR, 483 
Gaksch M, Verheyen N, Hollis BW, Rejnmark L, Karras SN, Hahn A, Bischoff-Ferrari HA, 484 
Reichrath J, Jorde R, Elmadfa I, Vieth R, Scragg R, Calvo MS, van Schoor NM, Bouillon R, 485 
Lips P, Itkonen ST, Martineau AR, Lamberg-Allardt C, Zittermann A. Rationale and Plan for 486 
Vitamin D Food Fortification: A Review and Guidance Paper. Front Endocrinol (Lausanne) 9: 373, 487 
2018. 488 
49. Pincikova T, Paquin-Proulx D, Sandberg JK, Flodström-Tullberg M, Hjelte L. Vitamin D 489 
treatment modulates immune activation in cystic fibrosis.  Clin Exp Immunol 189: 359-371, 2017. 490 
50. Quesada-Gomez JM, Entrenas Castillo M, Bouillon R. Vitamin D Receptor Stimulation to 491 
Reduce Acute Respiratory Distress Syndrome (ARDS) in Patients With Coronavirus SARS-CoV-2 492 
Infections. Steroid Biochem Mol Biol 105719, 2020. doi: 10.1016/j.jsbmb.2020.105719. 493 
Downloaded from journals.physiology.org/journal/ajplung (186.058.135.140) on October 30, 2020.
19 
 
51. Quraishi SA, Bittner EA, Blum L, Hutter MM, Camargo CA Jr. Association between 494 
preoperative 25-hydroxyvitamin D level and hospital-acquired infections following Roux-en-Y gastric 495 
bypass surgery. JAMA Surg 149(2): 112-8, 2014.  496 
52. Rhodes JM, Subramanian S, Laird E, Kenny RA. Editorial: Low population mortality from 497 
COVID‐19 in countries south of latitude 35 degrees North - supports vitamin D as a factor determining 498 
severity. Aliment Pharmacol Ther  2020. doi: 10.1111/apt.15777. 499 
53. Sabetta JR, DePetrillo P, Cipriani RJ, Smardin J, Burns LA, Landry ML. Serum 25-500 
hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS 501 
One 5. e11088, 2010. doi:10.1371/journal.pone.0011088.  502 
54. Sandhu MS, Casale TB. The role of vitamin D in asthma. Ann Allergy Asthma Immunol 105: 191-503 
199, 2010. 504 
55. Santoro D, Caccamo D, Lucisano S, Buemi M, Sebekova K, Teta D, De Nicola L. Interplay of 505 
vitamin D, erythropoiesis, and the renin-angiotensin system. Biomed Res Int 2015: 145828, 2015. 506 
https://doi.org/10.1155/2015/145828. 507 
56. Shi Y, Liu T, Yao L, Xing Y, Zhao X, Fu J, Xue X. Chronic vitamin D deficiency induces lung 508 
fibrosis through activation of the renin-angiotensin system. Sci Rep 7: 3312, 2017. 509 
https://doi.org/10.1038/s41598-017-03474-6. 510 
57. Shirvani A, Kalajian TA, Song A, Holick MF. Disassociation of Vitamin D's Calcemic Activity 511 
and Non-calcemic Genomic Activity and Individual Responsiveness: A Randomized Controlled 512 
Double-Blind Clinical Trial. Sci Rep 9: 17685, 2019. doi:10.1038/s41598-019-53864-1. 513 
58. Silvagno F, De Vivo E, Attanasio A, Gallo V, Mazzucco G, Pescarmona G. Mitochondrial 514 
localization of vitamin D receptor in human platelets and differentiated megakaryocytes. PLos One 5: 515 
e8670, 2010. doi: 10.1371/journal.pone.0008670. 516 
59. Sun ML, Yang JM, Sun YP, Su GH.  Inhibitors of RAS Might Be a Good Choice for the 517 
Therapy of COVID-19 Pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 43(0): E014, 2020. 518 
doi:10.3760/cma.j.issn.1001-0939.2020.0014. 519 
Downloaded from journals.physiology.org/journal/ajplung (186.058.135.140) on October 30, 2020.
20 
 
60. Taher YA, van Esch BCAM, Hofman GA, Henricks PAJ, van Oosterhout AJM. 1α,25-520 
Dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model 521 
of allergic asthma: role for IL-10 and TGFbeta. J Immunol 180: 5211e21, 2008. 522 
doi.org/10.4049/jimmunol.180.8.5211. 523 
61. Takano Y, Mitsuhashi H, Ueno K. 1α,25-Dihydroxyvitamin D₃ inhibits neutrophil recruitment in 524 
hamster model of acute lung injury. Steroids 76: 1305-1309, 2011. 525 
62. Tan WSD, Liao W, Zhou S, Mei D, Wong WF. Targeting the renin-angiotensin system as novel 526 
therapeutic strategy for pulmonary diseases. Curr Opin Pharmacol 40: 9-17, 2018. 527 
63. Tan ZX, Chen YH, Xu S, Qin HY, Zhang C, Zhao H, Xu DX. Calcitriol inhibits bleomycin-528 
induced early pulmonary inflammatory response and epithelial-mesenchymal transition in mice. 529 
Toxicol Lett 240: 161-171, 2016.  530 
64. The association of UK Dietitians: Covid 19, Coronavirus - Advice for general Public. March 16, 531 
2020. https://www.bda.uk.com/resource/covid-19-corona-virus-advice-for-the-general-public.html 532 
65. Tian WM, Yang YG, Shang YX, Cai XX, Chen WW, Zhang H. Role of 1,25-dihydroxyvitamin 533 
D3 in the treatment of asthma. Eur Rev Med Pharmacol Sci 18: 1762-1769, 2014. 534 
66. Topilski I, Flaishon L, Naveh Y, Harmelin A, Levo Y, Shachar I. The anti-inflammatory effects 535 
of 1,25-dihydroxyvitamin D3 on Th2 cells in vivo are due in part to the control of integrin-mediated T 536 
lymphocyte homing. Eur J Immunol 34: 1068e76, 2004. doi.org/10.1002/eji.200324532. 537 
67. Trochoutsou AI, Kloukina V, Samitas K, Xanthou G. Vitamin-D in the Immune System: 538 
Genomic and Non-Genomic Actions. Mini Rev Med Chem 15(11): 953-63, 2015. 539 
68. Turin A, Bax JJ, Doukas D, Joyce C, Lopez JJ, Mathew V, Pontone G, Shah F, Singh S, 540 
Wilber DJ, Rabbat MG. Interactions Among Vitamin D, Atrial Fibrillation, and the Renin-541 
Angiotensin-Aldosterone System. Am J Cardiol 122: 780–784, 2018.  542 
69. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-543 
Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 382(17):1653-544 
1659, 2020. 545 
Downloaded from journals.physiology.org/journal/ajplung (186.058.135.140) on October 30, 2020.
21 
 
70. Vuichard Gysin D, Dao D, Gysin CM, Lytvyn L, Loeb M. Effect of Vitamin D3 546 
Supplementation on Respiratory Tract Infections in Healthy Individuals: A Systematic Review and 547 
Meta-Analysis of Randomized Controlled Trials. PLoS One 11: e0162996, 2016. 548 
71. Wacker M, Holick MF. Sunlight and Vitamin D. A global perspective for health 549 
Dermatoendocrinol 5(1): 51-108, 2013. 550 
72. Wang Y, Yang Z, Gao L, Cao Z, Wang Q. Effects of a single dose of vitamin D in septic 551 
children: a randomized, double-blinded, controlled trial.  Int Med Res 48(6): 300060520926890, 552 
2020. doi: 10.1177/0300060520926890. 553 
73. Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H. Vitamin D alleviates lipopolysaccharide-554 
induced acute lung injury via regulation of the renin-angiotensin system. Mol Med Rep 16: 7432–7438, 555 
2017.  556 
74. Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, Pridgeon C,  557 
Dallman M, Loke TK, Robinson DS, Barrat FJ, O'Garra A, Lavender P, Lee PH, Corrigan C, 558 
Hawrylowicz CM. Reversing the defective induction of IL-10-secreting regulatory T cells in 559 
glucocorticoid-resistant asthma patients. J Clin Invest 116: 146e55, 2006. 560 
75. Yao L, Shi Y, Zhao X, Hou A, Xing Y, Fu J, Xue X. Vitamin D attenuates hyperoxia-induced 561 
lung injury through downregulation of Toll-like receptor 4.  Int J Mol Med 39: 1403-1408, 2017. 562 
76. Zemb P, Bergman P, Camargo CA Jr, Cavalier E, Cormier C, Courbebaisse M, Hollis B, 563 
Minisola S, Pilz S, Pludowski P, Schmitt F, Zdrenghea M, Souberbielle JC. Vitamin D deficiency 564 
and COVID-19 pandemic. J Glob Antimicrob Resist 22: 133-134, 2020. 565 
77. Zhang H, Yang N, Wang T, Dai B, Shang Y. Vitamin D reduces inflammatory response in 566 
asthmatic mice through HMGB1/TLR4/NF κB signaling pathway.  Mol Med Rep 17: 2915-2920, 567 
2018.  568 
 569 
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Cellular interactions of angiotensin and vitamin D receptors  572 
RXR: retinoid X receptor; RAS: renin-angiotensin system; VDRE: Vitamin D response element; 573 
1,25(OH)2D3: 1,25-dihydroxyvitamin D3 (20).   574 
 575 
Figure 2 576 
Graphic overview of vitamin D main signaling pathways as a new potential treatment in 577 
COVID-19 lung infection 578 
Solid lines indicate stimulation/induction, while dashed lines indicate inhibition/blocking. 579 
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